Boston Scientific Faces Securities Fraud Lawsuit Over Alleged Misrepresentation of Electrophysiology Demand
Boston Scientific Corporation (BSX) is facing a securities fraud lawsuit, with institutional investors potentially seeking lead plaintiff status in a class action. The stock experienced a significant drop of 17.6% on February 4, 2026, following the alleged concealment of weaknesses in the company's electrophysiology business. The deadline to apply for lead plaintiff appointment is set for May 4, 2026.
Tickers: $BSX
Topics: Boston Scientific ERISA institutional investors lead plaintiff portfolio losses securities class action